All In Biotech

NDA 213591 · Novartis Pharm

Tabrecta

Capmatinib Hydrochloride · Oral

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Mar 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

May 6, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

52

5 Phase 3, 6 recruiting

FAERS reports

2,366

1,429 serious, 571 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 26, 2026.

TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Mechanism: Capmatinib is a kinase inhibitor that targets MET, including the mutant variant produced by exon 14 skipping. MET exon 14 skipping results in a protein with a missing regulatory domain that reduces its negative regulation leading to increased downstream MET signaling. Capmatinib inhibited cancer cell growth driven by a mutant MET variant lacking exon 14 at clinically achievable concentrations and demonstrated anti-tumor activity in murine tumor xenograft models derived from human lung tumors with either a mutation leading to MET exon 14 skipping or MET amplification. Capmatinib inhibited the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 10, 2022 Supplement 4 · Efficacy · priority review LetterLabel
  • May 6, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
  • TABRECTA · CAPMATINIB HYDROCHLORIDE EQ 150MG BASE · TABLET, ORAL · Prescription
  • TABRECTA · CAPMATINIB HYDROCHLORIDE EQ 200MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Capmatinib" as an intervention, any sponsor and status, largest first.

All 52 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death417
  • peripheral swelling289
  • fatigue262
  • oedema peripheral247
  • nausea241
  • malignant neoplasm progression182
  • dyspnoea141
  • oedema134
  • asthenia113
  • decreased appetite98
  • non-small cell lung cancer95
  • joint swelling93

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20193
2020253
2021642
2022643
2023488
2024145
2025129
202662

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tabrecta (Capmatinib Hydrochloride)

2024 spending

$124M

Beneficiaries

1,169

6,477 claims

Per beneficiary

$106,164

$197.14 per unit

View as table
YearSpending
2020$17,063,605
2021$50,107,244
2022$70,283,872
2023$93,104,407
2024$124,105,409

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 25 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.